阿那白滞素治疗伴持续性或复发性心包炎的缩窄性心包炎
该前瞻性队列研究纳入39例激素依赖且秋水仙碱抵抗的复发性或持续性心包炎患者,接受阿那白滞素100 mg每日一次皮下注射,随访中8例(20%)诊断为缩窄性心包炎,其中5例(63%)心包缩窄完全缓解,3例(37%)需心包切除术;持续性病程与缩窄性心包炎风险升高相关(HR 30.6,95%CI 3.69至253.09)。
要点
- 阿那白滞素可能逆转缩窄性心包炎,5/8例完全缓解。
- 持续性心包炎病程较复发性更易发生缩窄性心包炎。
- 激素依赖且秋水仙碱抵抗者需警惕缩窄性心包炎。
核心结论
- 在复发性或持续性心包炎患者中,阿那白滞素可能有助于缩窄性心包炎的逆转。
- 缩窄性心包炎风险与持续性病程而非复发性病程相关。
研究设计与样本
- 前瞻性队列研究,2015至2018年纳入39例激素依赖且秋水仙碱抵抗的复发性或持续性心包炎连续患者。
- 患者接受阿那白滞素100 mg每日一次皮下注射,并在1、3、6个月及之后每6个月进行临床和超声心动图随访。
主要发现
- 随访期间8/39(20%)患者诊断为缩窄性心包炎。
- 阿那白滞素100 mg/日后,5例(63%)心包缩窄完全缓解,中位时间1.2个月(IQR 1-4)。
- 另3例(37%)缩窄性心包炎转为慢性,中位2.8个月(IQR 2-5)内需心包切除术。
- 11例(28%)持续性病程患者发生缩窄性心包炎,持续性病程与缩窄性心包炎风险升高相关(HR 30.6,95%CI 3.69至253.09)。
临床怎么用
- 对激素依赖且秋水仙碱抵抗的复发性或持续性心包炎患者,可考虑阿那白滞素作为三线治疗以逆转缩窄性心包炎并避免心包切除术。
- 持续性心包炎病程患者应加强缩窄性心包炎的监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Frequent flares of pericardial inflammation in recurrent or incessant pericarditis with corticosteroid dependence and colchicine resistance may represent a risk factor for constrictive pericarditis (CP). This study was aimed at the identification of CP in these patients, evaluating the efficacy and safety of anakinra, a third-line treatment based on interleukin-1 inhibition, to treat CP and prevent the need for pericardiectomy. METHODS: Consecutive patients with recurrent or incessant pericarditis with corticosteroid dependence and colchicine resistance were included in a prospective cohort study from 2015 to 2018. Enrolled patients received anakinra 100 mg once daily subcutaneously. The primary end point was the occurrence of CP. A clinical and echocardiographic follow-up was performed at 1, 3, 6 months and then every 6 months. RESULTS: Thirty-nine patients (mean age 42 years, 67% females) were assessed, with a baseline recurrence rate of 2.76 flares/patient-year and a median disease duration of 12 months (IQR 9-20). During follow-up, CP was diagnosed in 8/39 (20%) patients. After anakinra dose of 100 mg/day, 5 patients (63%) had a complete resolution of pericardial constriction within a median of 1.2 months (IQR 1-4). In other three patients (37%), CP became chronic, requiring pericardiectomy within a median of 2.8 months (IQR 2-5). CP occurred in 11 patients (28%) with incessant course, which was associated with an increased risk of CP over time (HR for CP 30.6, 95% CI 3.69 to 253.09). CONCLUSIONS: In patients with recurrent or incessant pericarditis, anakinra may have a role in CP reversal. The risk of CP is associated with incessant rather than recurrent course.
引用
- Andreis A, Imazio M, Giustetto C, et al. Anakinra for constrictive pericarditis associated with incessant or recurrent pericarditis. Heart. 2020. PMID: 32868281. doi:10.1136/heartjnl-2020-316898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。